Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure
| dc.contributor.author | Semmler, Georg | |
| dc.contributor.author | Alonso Lopez, Sonia | |
| dc.contributor.author | Pons, Monica | |
| dc.contributor.author | Lens García, Sabela | |
| dc.contributor.author | Dajti, Elton | |
| dc.contributor.author | Griemsmann, Marie | |
| dc.contributor.author | Zanetto, Alberto | |
| dc.contributor.author | Burghart, Lukas | |
| dc.contributor.author | Hametner-Schreil, Stefanie | |
| dc.contributor.author | Hartl, Lukas | |
| dc.contributor.author | Manzano, Marisa | |
| dc.contributor.author | Rodríguez Tajes, Sergio | |
| dc.contributor.author | Zanaga, Paola | |
| dc.contributor.author | Schwarz, Michael | |
| dc.contributor.author | Gutierrez, María L. | |
| dc.contributor.author | Jachs, Mathias | |
| dc.contributor.author | Pocurull Aparicio, Anna | |
| dc.contributor.author | Polo Lorduy, Benjamín | |
| dc.contributor.author | Ecker, Dominik | |
| dc.contributor.author | Mateos, Beatriz | |
| dc.contributor.author | Izquierdo, Sonia | |
| dc.contributor.author | Real, Yolanda | |
| dc.contributor.author | Balcar, Lorenz | |
| dc.contributor.author | Carbonell-Asins, Juan A. | |
| dc.contributor.author | Gschwantler, Michael | |
| dc.contributor.author | Russo, Francesco P. | |
| dc.contributor.author | Azzaroli, Francesco | |
| dc.contributor.author | Maasoumy, Benjamin | |
| dc.contributor.author | Reiberger, Thomas | |
| dc.contributor.author | Forns Bernhardt, Xavier | |
| dc.contributor.author | Genescà, Joan | |
| dc.contributor.author | Bañares, Rafael | |
| dc.contributor.author | Mandorfer, Mattias | |
| dc.contributor.author | cACLD-SVR Study Group | |
| dc.date.accessioned | 2026-03-02T15:30:03Z | |
| dc.date.available | 2026-03-02T15:30:03Z | |
| dc.date.issued | 2025-02-01 | |
| dc.date.updated | 2026-03-02T09:28:37Z | |
| dc.description.abstract | Background & Rationale: Around 750.000 patients/year will be cured from hepatitis C-virus (HCV)-infection until 2030. Those with compensated advanced chronic liver disease (cACLD) remain at risk for hepatic decompensation and de-novo hepatocellular carcinoma (HCC). Algorithms have been developed to stratify risk early after cure, however, data on long-term outcome and the prognostic utility of these risk stratification algorithms at later timepoints are lacking. Main Results: We retrospectively analysed a cohort of 2335 cACLD-patients (LSM >= 10kPa) who achieved HCV-cure by interferon-free therapies from 15 European centres (median age 60.2 +/- 11.9 y, 21.1% obesity, 21.2% diabetes). During a median follow-up of 6 years, first hepatic decompensation occurred in 84 patients (3.6%, incidence rate [IR]: 0.74%/year, cumulative incidence at 6 y: 3.2%); 183 (7.8%) patients developed de-novo HCC (IR: 1.60%/year, cumulative incidence at 6 y: 8.3%), with both risks being strictly linear over time. Baveno VII criteria to exclude (FU-LSM 150 G/L) or rule-in (FU-LSM >= 25kPa) clinically significant portal hypertension (CSPH) stratified the risk of hepatic decompensation with proportional hazards. Estimated probability of CSPH discriminated patients developing versus not developing hepatic decompensation in the grey-zone (i.e., patients meeting none of the above criteria). Published HCC risk stratification algorithms identified high- and low-incidence groups, however, the size of the latter group varied substantially (9.9%-69.1%). A granular 'HCC-SVR' model was developed to inform on an individual patient's HCC-risk after HCV-cure. Conclusion: In patients with cACLD, the risks of hepatic decompensation and HCC remain constant after HCV-cure, even in the long-term (>3 y). One-time post-treatment risk stratification based on non-invasive criteria provides important prognostic information that is maintained during long-term follow-up, as the hazards remain proportional over time. | |
| dc.format.extent | 51 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idimarina | 9447539 | |
| dc.identifier.issn | 1527-3350 | |
| dc.identifier.pmid | 39817915 | |
| dc.identifier.uri | https://hdl.handle.net/2445/227774 | |
| dc.language.iso | eng | |
| dc.publisher | American Association for the Study of Liver Diseases | |
| dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1097/HEP.0000000000001005 | |
| dc.relation.ispartof | HEPATOLOGY, 2025, vol. 81, num. 2, p. 609-624 | |
| dc.relation.uri | https://doi.org/10.1097/HEP.0000000000001005 | |
| dc.rights | (c) Wolters Kluwer Health, 2025 | |
| dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | |
| dc.subject.classification | Infeccions per coronavirus | |
| dc.subject.classification | Cirurgia hepàtica | |
| dc.subject.classification | Hepatitis | |
| dc.subject.other | Coronavirus infections | |
| dc.subject.other | Liver surgery | |
| dc.subject.other | Hepatitis | |
| dc.title | Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/acceptedVersion |
Fitxers
Paquet original
1 - 1 de 1
Carregant...
- Nom:
- SEMMLERALONSOLOPEZ_LONGTERM_RISK__unificat.2pdf.pdf
- Mida:
- 622.01 KB
- Format:
- Adobe Portable Document Format